Abstract:Objective To establish the evaluation criteria on rational use of albumin-bound paclitaxel (nab-paclitaxel), and analyze the application of nab-paclitaxel in Hunan Cancer Hospital so as to provide reference for rational use of nab-paclitaxel.Methods Referring to drug utilization evaluation (DUE) criteria, the DUE criteria of nab-paclitaxel was established on the base of the specification approved by CFDA, FDA and PMDA, and NCCN and CSCO guidelines. And the use of nab-paclitaxel in 108 patients was evaluated according to the criteria.Results The main unreasonable applications of nab-paclitaxel were as follows: 51 cases (47.2%) were unreasonable in indications, 43 cases (75.4%) in usage and dosage, 10 cases (17.5%) in combination, 73 cases (67.6%) in routine blood monitoring during treatment period, and 47 cases (43.5%) in pretreatment for vomit-stopping. Off-label use was also common. Among the 108 reviewed cases, 9 cases (8.3%) had nab-paclitaxel used in line with the indications, but off-label use occurred in 99 cases (91.7%), including 48 cases (48.5%) of off-label use with evidence.Conclusion The established DUE criteria of nab-paclitaxel had a good practicability and were conducive to promote rational drug use in the clinic.